Neoadjuvant Treatment with Cetuximab, 5-Fluorouracil, Folinic Acid and Oxaliplatin in Unresectable Retroperitoneal Recurrent Colon Cancer

Zusammenfassung

Eine wirksame neoadjuvante Chemotherapie kann bei ausgesuchten Patienten mit kolorektalem Karzinom und hepatischer Metastasierung zu sekundärer Resektabilität führen. Wir berichten über einen Patienten mit einem retroperitonealem lokoregionären Rezidiv eines Kolonkarzinoms, der mit einer Kombinationstherapie mit infusionalem 5-Fluorouracil, Folinsäure, Oxaliplatin und Cetuximab behandelt wurde. Nach 12 Wochen Therapiedauer konnte ein partielles Tumoransprechen erzielt werden. Weitere 3 Wochen später wurde der Patient operiert und der Tumor ohne perioperative Komplikationen komplett reseziert. Diese Kasuistik zeigt, dass eine neoadjuvante Behandlung mit molekular gezielten Therapeutika in Kombination mit Chemotherapie ebenfalls bei ausgesuchten Patienten mit lokoregionärem Rezidiv eine sekundäre kurative operative Sanierung erlauben kann.

Abstract

Some patients with initially unresectable hepatic colorectal cancer metastases can be effectively treated with neoadjuvant chemotherapy to allow operative resection in curative intent. Here, we report on a patient with unresectable locoregional recurrence of colon cancer, which was down-staged using combination chemotherapy with infusional 5-fluorouracil, folinic acid, oxaliplatin and cetuximab. After 12 weeks of therapy a partial response was documented and 3 weeks later the tumor was completely resected without increased perioperative morbidity. Therefore, neoadjuvant treatment with molecular targeted agents in combination with chemotherapy can also be an option to enable selected patients with locoregional recurrence to undergo surgical resection in curative intent.

Schlüsselwörter

Kolonkarzinom - lokoregionäres Rezidiv - neoadjuvante Therapie - molekular gezielte Therapie - Chirurgie

Key words

colon cancer - locoregional recurrence - neoadjuvant treatment - molecular targeted therapy - surgery

References

• 1 Goldberg R M, Fleming T R, Tangen C M. et al . Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.  Ann Intern Med. 1998;  129 27-35
• 2 Bowne W B, Lee B, Wong W D. et al . Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases.  Dis Colon Rectum. 2005;  48 897-909
• 3 Hurwitz H, Fehrenbacher L, Novotny W. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 4 Cunningham D, Humblet Y, Siena S. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
• 5 Ellis L M, Curley S A, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.  J Clin Oncol. 2005;  23 4853-4855
• 6 Gruenberger B, Scheithauer W, Tamandl D. et al . Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with respectable colorectal cancer liver metastases. ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2007;  25 (20 Suppl) A-4060
• 7 D’Angelica M, Kornprat P, Gonen M. et al . Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.  Ann Surg Oncol. 2007;  14 759-765
• 8 Van Cutsem E, Nowacki M, Lang I. et al . Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2007;  25 (20 Suppl) A-4000
• 9 Bokemeyer C, Bondarenko I, Makhson A. et al . Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2007;  25 (20 Suppl) A-4035
• 10 Borner M, Mingrone W, Koeberle D. et al . The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2006;  24 (20 Suppl) A-3551
• 11 Andre T, Tabernero J, Van Cutsem E. et al .Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. Orlando, FL, USA; Gastrointestinal Cancers Symposium 2007: A-334
• 12 Hofheinz R D, Horisberger K, Woernle C. et al . Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.  Int J Radiat Oncol Biol Phys. 2006;  66 1384-1390
• 13 Arnold D, Hipp M, Liersch T. et al . Cetuximab, capecitabine, and oxaliplatin (Cet-CapOx) with concurrent radiotherapy (RT) in advanced rectal cancer (RC): Results of a phase I/II trial. ASCOAnnual Meeting Proceedings Part I.  J Clin Oncol. 2007;  25 (20 Suppl) A-4042